The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

H. Lee Moffitt Cancer Center and Research Institute

Status: Active, not recruiting

Conditions: FAP; Chronic Pancreatitis; Genetic Pancreatic Cancer; PALB2 Gene Mutation; Genetic Pancreatitis; Familial Atypical Multiple Mole-Melanoma; Pancreatic Ductal Adenocarcinoma; Peutz-Jeghers Syndrome; BRCA Mutation; Lynch Syndrome; Pancreatic Cyst; Ataxia Telangiectasia; Fatty Pancreas

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT05692596

MCC-22156

Details and patient eligibility

About

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Enrollment: 317 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• 18 years of age or older
• Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
• Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
• Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Trial design

317 participants in 1 patient group

All participants

Description:

Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.

Treatment:

Other: Data collection